Andrew Lloyd ALA
LightNews LightNews
banner
andrewlloydala.bsky.social
Andrew Lloyd ALA
@andrewlloydala.bsky.social
56 followers 290 following 120 posts
International PR group | Market communications for life sciences & tech 🚀 | 35+ years in #biotech #medtech 💉 #electronics #photonics 🛰️ #startups #VC
http://ala.associates
Posts Replies Media Videos
andrewlloydala.bsky.social
Wishing you all a great year in 2026!

2025 has been a busy year for our clients with 67 news announcements, countless interviews and dozens of social media posts.

As a result, more than 2,300 clippings!

We thank our clients and partners for their trust. Kudos to the team for their achievements!
January 5, 2026 at 10:34 AM
andrewlloydala.bsky.social
[ALA Client News] Novadip recruits first pediatric patients in pivotal phase 3 trial of tissue regenerative treatment NVD003 in congenital pseudoarthrosis of the tibia

ala.associates/clinical/nov...

#biotech #orphandisease
December 15, 2025 at 9:02 AM
andrewlloydala.bsky.social
[ALA Client News] PLL Therapeutics opens subsidiary in New Zealand to accelerate ALS (Amyotrophic Lateral Sclerosis) treatment and early diagnostics breakthroughs

ala.associates/corporate/pl...

#biotech #ALS #subsidiary
December 10, 2025 at 10:03 AM
andrewlloydala.bsky.social
[ALA Client News] Provepharm expands presence in medical dyes and enters fluorescence era

ala.associates/corporate/pr...

#pharma #surgicaldyes #fluorescence
December 10, 2025 at 8:02 AM
andrewlloydala.bsky.social
[ALA Client News] SeaBeLife enters into joint development agreement with Unither Pharmaceuticals to formulate and produce ophthalmic drug candidate

ala.associates/partnership/...

#biotech #ophthalmology
December 8, 2025 at 9:02 AM
andrewlloydala.bsky.social
[ALA Client News] BiPER Therapeutics secures €1M investment to advance first-in-class cancer therapy into clinical trials

ala.associates/funding/bipe...

#funding #cancer #clinicaltrials
December 2, 2025 at 10:00 AM
andrewlloydala.bsky.social
[ALA Client News] Axoltis Pharma raises €18 million to accelerate development of Amyotrophic Lateral Sclerosis (ALS) drug candidate

ala.associates/funding/axol...

#ALS #funding #phase2trial
December 2, 2025 at 8:02 AM
andrewlloydala.bsky.social
[ALA Client News] Archeon Medical: first responder study shows novel ventilation device triples survival rates without brain damage in #cardiacarrest care - US clinical trials to follow

ala.associates/clinical/arc...
November 18, 2025 at 10:02 AM
andrewlloydala.bsky.social
[ALA Client News] Adaptam Therapeutics raises €3 million to pioneer cancer immunotherapies against immunosuppressive myeloid cells

👉 ala.associates/funding/adap...

#oncology #biotech
October 27, 2025 at 9:45 AM
andrewlloydala.bsky.social
[ALA Client News] Naobios and Tokyo Metropolitan Institute of Medical Science partner to develop new live-attenuated vaccine against mpox

Partnership aims to commercialize new mpox vaccine - with higher level of safety - by 2027

ala.associates/partnership/...
#vaccine #mpox
October 23, 2025 at 11:01 AM
andrewlloydala.bsky.social
[ALA Client News] Meteor Biotech launches in Europe with first deployment of spatial biology platform, CosmoSort, at VIB in Belgium

👉 ala.associates/product-laun...

#SpatialBiology #Cancer #DrugDevelopment
October 21, 2025 at 1:00 PM
andrewlloydala.bsky.social
[ALA Client News] Exeliom Biosciences secures €2.85M extension to Series A funding, bringing total round to nearly €12M

ala.associates/funding/exel...

#fundraising #immunomodulation #inflammatorydisease #oncology
October 21, 2025 at 9:01 AM
andrewlloydala.bsky.social
[ALA Client News] SOM Biotech secures clear registrational path for SOM3355 in Huntington’s disease after @fda.gov End of Phase 2 Meeting

ala.associates/regulatory/s...

#huntingtonsdisease #neurology
October 20, 2025 at 9:04 AM
andrewlloydala.bsky.social
[ALA client news] Avec le soutien de ses actionnaires historiques Téthys Invest, CVC et La Caisse (ex-CDPQ), Sebia annonce l’entrée en négociations exclusives en vue d’accueillir Warburg Pincus à son capital

#diagnostic #oncologie ala.associates/corporate/se...
Avec le soutien de ses actionnaires historiques – Téthys Invest, CVC et La Caisse (précédemment CDPQ) – Sebia est heureux d’annoncer l’entrée en négociations exclusives en vue d’accueillir Warburg Pin...
ala.associates
October 16, 2025 at 9:35 AM
andrewlloydala.bsky.social
[ALA client news] Ciliatech opens US subsidiary and plans clinical trials in #glaucoma

Initiative follows recent CE mark of Ciliatech’s flagship eye implant, a novel treatment for patients with mild to moderate glaucoma

#glaucoma #USsubsidiary #clinicalresearch

ala.associates/corporate/ci...
Ciliatech opens US subsidiary and plans clinical trials in glaucoma | Andrew Lloyd & Associates
ala.associates
October 14, 2025 at 9:02 AM
andrewlloydala.bsky.social
🔬 From flexible implants to circuits seeded with living cells, a new kind of electronics is starting to produce long-lasting implants with the potential to help everything from paralysis to hearing and vision loss - @newscientist.com

www.newscientist.com/article/2492...

#technology #medtech
The futuristic new tech that could bridge broken nerves and mend minds
From flexible implants to circuits seeded with living cells, a new kind of electronics is starting to produce long-lasting implants with the potential to help everything from paralysis to hearing and ...
www.newscientist.com
October 9, 2025 at 7:53 AM
andrewlloydala.bsky.social
At ALA, we’re proud to partner with Ciloa, a biotech pioneer engineering small extracellular vesicles (sEVs) for therapeutic and preventive use 🧬

We helped raise awareness of its €6.5M funding for advancement of its therapeutic option for metabolic diseases, such as #diabetes and #obesity💡
October 2, 2025 at 12:26 PM
andrewlloydala.bsky.social
[ALA Client News] SeaBeLife secures €2 million

☑️ This funding will help fast-track the launch of clinical trials in dry AMD and severe acute hepatitis programs, with first clinical trial set to start in 2026

ala.associates/funding/seab...

#ophthalmology #funding #biotech
October 1, 2025 at 8:29 AM
andrewlloydala.bsky.social
[ALA Client News] RDS raises €14 million to industrialize MultiSense®,
a connected patch for remote patient monitoring

ala.associates/funding/rds-...

#medtech #funding #wearables
September 29, 2025 at 9:00 AM
andrewlloydala.bsky.social
[ALA Client News] Sonomind secures €3 million to advance its novel neuromodulation ultrasound device and opens a new therapeutic pathway in psychiatry and neurology

ala.associates/funding/sono...

@cnrs.fr @espciparispsl.bsky.social

#neurology #funding #neuromodulation #depression
September 24, 2025 at 9:04 AM
andrewlloydala.bsky.social
🖨️ #3DPrinting: Electronic devices that dissolve in water could make it easier to create and recycle technology prototypes – and they could even inspire more sustainable commercial devices - @jeremyhsu.bsky.social for @newscientist.com

www.newscientist.com/article/2493...

#sustainability
3D-printed electronics can dissolve in water for quick recycling
Electronic devices that dissolve in water could make it easier to create and recycle technology prototypes – and they could even inspire more sustainable commercial devices
www.newscientist.com
September 18, 2025 at 12:12 PM
andrewlloydala.bsky.social
[ALA Client News] Genoskin Raises $8.7M Series A to Advance Ethical, Human Based Models That Deliver Reliable Insights for Safer, More Predictive Drug Development

ala.associates/funding/geno...

#drugdevelopment #immunotoxicology #funding
September 16, 2025 at 9:05 AM
andrewlloydala.bsky.social
[ALA Client News] SOM Biotech receives positive EMA COMP opinion on European Orphan Drug Designation for SOM3355 for treatment of Huntington’s Disease

👉 ala.associates/regulatory/s...

#huntingtonsdisease #neurology
September 15, 2025 at 9:01 AM
andrewlloydala.bsky.social
Celebrating our clients' media successes🌟

Here are some of our recent highlights:

1️⃣ PLL Therapeutics in Drug Discovery World. PLL' CEO Jean-Pascal Zambaux presented the company's strategic approach for early detection and treatment of Amyotrophic Lateral Sclerosis (ALS) at Bioshares Biotech Summit
September 12, 2025 at 7:47 AM
andrewlloydala.bsky.social
[ALA Client News] Naobios, Nuvonis and European Vaccine Initiative collaborate on manufacturing influenza challenge agent

ala.associates/partnership/...

#biotech #vaccines
September 2, 2025 at 7:05 AM